bioRxivNeurosciencePreprint
Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-Aβ immunotherapy
Moustafa AlgamaliD, Shinya YokomizoiD, Wadzanai Ndambakuwa, Sarena Abdallah, Maria Virtudes Sanchez-MicoiD, Rebecca L. GillaniiD, Patrick da SilvaiD, Aryan Rajput, Lakshita Palanivelu, Yuna Lee, Katy R. WalshiD, Sunny Kumar, Kıvılcım KılıçiD, Joseph B. El KhouryiD, Saef IzzyiD, Mariel G. KozbergiD, Brian J. BacskaiiD
Abstract
Anti-amyloid {beta} (A{beta}) immunotherapy improves cognitive outcomes in Alzheimer's disease (AD) but is associated with amyloid-related imaging abnormalities (ARIA), through poorly understood mechanisms. To define how anti-A{beta} antibodies acutely engage brain immune and vascular compartments, we developed a longitudinal in vivo two-photon imaging platform to track microglial dynamics, peripheral immune cell recruitment, and vascular responses in APP/PS1 mice. Anti-A{beta} antibodies, including aducanumab and lecanemab, rapidly initiated microglial activation and spatial reorganization within 24 hours of dosing, with recruitment to plaque-associated regions, stabilizing plaque growth. Aducanumab and lecanemab also triggered a rapid and transient cerebrovascular immune response characterized by rolling and adhesion of peripheral immune cells along leptomeningeal vessels, accompanied by endothelial activation. Immune cell characterization revealed recruitment of innate immune cells (Iba1Ki67 monocytes and Ly6G neutrophils) and proliferative CD3 T cells into the vascular compartment following treatment. Prophylactic treatment with high-dose dexamethasone reduced the number of adherent cells without affecting microglial activation. Depletion of brain-resident immune cells similarly reduced peripheral immune cell recruitment, supporting their contribution to leukocyte recruitment. Postmortem brain tissue from an AD patient treated with lecanemab showed higher proliferation-associated monocyte signature scores, suggesting translational relevance to the proliferative myeloid response observed in our mouse models. These findings demonstrate that anti-A{beta} immunotherapy rapidly initiates a coordinated central and peripheral immune response at the leptomeningeal interface. These early immune-vascular interactions represent a plausible initiating mechanism for ARIA and provide a mechanistic framework to guide strategies for mitigating ARIA risk
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Anti-Aβ immunotherapy-mediated amyloid clearance attenuates microglial activation without inducing exhaustion at residual plaques
Lis de Weerd, Selina Hummel, … Christian Haass·bioRxiv·Apr 10, 2025
- Aβ Antibodies Target Not Only Amyloid Plaques But Also Distinct Brain Cells And Vessels
Gehua Wen, Nils Lindblom, … Gunnar K. Gouras·Alzheimer s & DementiaPeer-reviewed·Jan 1, 2026
- The Alzheimer's therapeutic Lecanemab induces an amyloid-clearing program in microglia
Giulia Albertini, Magdalena Zielonka, … Bart De Strooper·bioRxiv·Jul 24, 2025
- Intravenous anti-abeta immunotherapy acutely increases cerebral amyloid angiopathy and vascular damages in APOE4 mice
Philip Pikus, Gracie S. Healey, … George William Rebeck·bioRxiv·Feb 11, 2026
- Lecanemab Blocks the Effects of the Aβ/Fibrinogen Complex on Blood Clots and Synapse Toxicity in Organotypic Culture
P. K. Singh, E. N. Simoes-Pires, … E. H. Norris·Proceedings of the National Academy of SciencesPeer-reviewed·Apr 15, 2024
- Vicious circle of amyloid and leptomeningeal macrophages evokes vascular dysfunction in CAA
Rahadian Yudo Hartantyo, Takahiro Tsuji, … Hiroaki Wake·bioRxiv·Feb 14, 2026